Inside STAT: GSK partners with CRISPR pioneer Doudna to search for new drugs

Pharma giant GlaxoSmithKline is partnering with CRISPR co-inventor Jennifer Doudna to use the gene-editing technology toward the development of new medicines. The partnership will also involve the creation of a new lab — the Laboratory for Genomic Research — in San Francisco with up to $67 million in funding over the next five years. Doudna will be leading the new effort, but will be joined by Jonathan Weissman, a UCSF researcher whose work involves using CRISPR to understand individual human genes. Read more about the new effort — from its beginnings over dinner at Garibaldi’s in San Francisco to how the lab will be a new model of academic-pharma partnership — from STAT’s Matthew Herper.